Shares of Eli Lilly plummeted 14% on Thursday, pacing what would be the stock’s largest loss in decades after the pharmaceutical giant unveiled data for its obesity treatment pill that fell behind ...

On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year. By Gina Kolata People who were overweight or had obesity lost a ...

Eli Lilly's shares have increased by about 10% over the past month. Clinical progress in the past few weeks has helped solidify its lead in the weight loss market. The company's prospects remain ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage study that sets the stage for a new entrant to the obesity market next year.

Lilly's orforglipron shows superior weight loss and blood sugar control Highest dose of the pill leads to 9.2% weight reduction Detailed trial results to be presented at future medical meeting The ...

U.S. pharmaceutical giant Eli Lilly (LLY) has announced plans to spend $6.5 billion building a new state-of-the-art manufacturing plant in Houston, Texas, that will produce its upcoming weight-loss ...

HOUSTON – Before the State of Harris County address, Greater Houston Partnership President & Chief Executive Officer Steve Kean said, “We’ve got a big one coming. Going to invest billions of dollars.” ...

Sept 16 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday it will invest $5 billion to build a manufacturing facility in Virginia, part of the drugmaker's broader $27 billion plan to build ...